Schedule 13D
Item 1. Security and Issuer
This amendment No. 2 to Schedule 13D amends and supplements statements on Schedule 13D originally filed November 10, 2020, as amended by Amendment No. 1 thereto filed on November 20, 2020 (the “Schedule 13D”), which relates to the common stock, $0.001 par value (the “Teladoc Common Stock”) of Teladoc Health, Inc. (the “Issuer” or “Teladoc”) having its principal executive office at 2 Manhattanville Road, Suite 203 Purchase, New York 10577.
Item 2. Identity and Background.
There are no amendments to Item 2 of the Schedule 13D.
Item 3. Source and Amount of Funds or Other Consideration.
Item 3 of the Schedule 13D is hereby amended and supplemented as follows:
On November 2, 2020, General Catalyst Group VI, L.P. (“GC VI”) sold 275,226 shares of the Issuer’s Common Stock in open market transactions at prevailing market prices for gross proceeds of $52,860,029.95. On November 3, 2020, GC VI sold 341,746 shares of the Issuer’s Common Stock in open market transactions at prevailing market prices for gross proceeds of $65,639,348.30. On November 3, 2020, GC VI distributed, in-kind, without consideration, a total of 1,329,020 shares of the Issuer’s Common Stock to its general and limited partners. On March 12, 2021 GC IV distributed, in-kind, without consideration, a total of 1,051,396 shares of the Issuer’s Common Stock to its general and limited partners.
On November 2, 2020, General Catalyst Group VIII, L.P. (“GC VIII”) sold 19,168 shares of the Issuer’s Common Stock in open market transactions at prevailing market prices for gross proceeds of $3,639,139.46. On November 3, 2020, GC VIII sold 23,802 shares of the Issuer’s Common Stock in open market transactions at prevailing market prices for gross proceeds of $4,613,684.97. On November 3, 2020, GC VIII distributed, in-kind, without consideration, a total of 92,558 shares of the Issuer’s Common Stock to its general and limited partners. On March 11, 2021, GC VIII sold 72,549 shares of the Issuer’s Common Stock in open market transactions at prevailing market prices for gross proceeds of $14,386,694.36.
On November 2, 2020, General Catalyst Group VIII Supplemental, L.P. (“GC VIII Supplemental”) sold 57,099 shares of the Issuer’s Common Stock in open market transactions at prevailing market prices for gross proceeds of $10,840,541.97. On November 3, 2020, GC VIII Supplemental sold 70,902 shares of the Issuer’s Common Stock at prevailing market prices for gross proceeds of 13,743,376.43. On November 3, 2020, GC VIII Supplemental distributed, in-kind, without consideration, a total of 275,720 shares of the Issuer’s Common Stock to its general and limited partners. On March 12, 2021 GC VIII Supplemental distributed, in-kind, without consideration, a total of 218,124 shares of the Issuer’s Common Stock to its general and limited partners.
On November 2, 2020, GC Venture LH Manager, LLC distributed, in-kind, without consideration, a total of 387,119 shares of the Issuer’s Common Stock to its general and limited partners.
On November 2, 2020, GCGM Investment Holdings, LP (“GCGM IH”) distributed, in-kind, without consideration, a total of 44,441 shares of the Issuer’s Common Stock to members, which shares it had previously received through a distribution in-kind. On December 10, 2020, GCGM IH sold 4,900 shares of the Issuer’s Common Stock in open market transactions at prevailing market prices for gross proceeds of $966,935.21.
On November 2, 2020, General Catalyst Group Management Holdings, L.P. (“GCGM LP”) sold 63,532 shares of the Issuer’s Common Stock, in open market transactions at prevailing market prices for gross proceeds of $12,314,802.79, which shares it had previously received through a distribution in-kind. On November 3, 2020, GCGM LP sold 50,933 shares of the Issuer’s Common Stock in open market transactions at prevailing market prices for gross proceeds of $9,669,893.66, which shares it had previously received through a distribution in-kind. On November 10, 2020, GCGM LP sold 3,601 shares of the Issuer’s Common Stock in open market transactions at prevailing market prices for gross proceeds of $639,937.45, which shares it had previously received through a distribution in-kind. On November 18, 2020, GCGM LP distributed 196,592 shares of the Issuer’s Common Stock to members, which shares it had previously received through a distribution in-kind.